Jun J Yang1, Wendy Landier2, Wenjian Yang2, Chengcheng Liu2, Lindsey Hageman2, Cheng Cheng2, Deqing Pei2, Yanjun Chen2, Kristine R Crews2, Nancy Kornegay2, F Lennie Wong2, William E Evans2, Ching-Hon Pui2, Smita Bhatia2, Mary V Relling2. 1. Jun J. Yang, Wenjian Yang, Chengcheng Liu, Cheng Cheng, Deqing Pei, Kristine R. Crews, Nancy Kornegay, William E. Evans, Ching-Hon Pui, and Mary V. Relling, St Jude Children's Research Hospital, Memphis, TN; and Wendy Landier, Lindsey Hageman, Yanjun Chen, F. Lennie Wong, and Smita Bhatia, City of Hope, Duarte, CA. jun.yang@stjude.org. 2. Jun J. Yang, Wenjian Yang, Chengcheng Liu, Cheng Cheng, Deqing Pei, Kristine R. Crews, Nancy Kornegay, William E. Evans, Ching-Hon Pui, and Mary V. Relling, St Jude Children's Research Hospital, Memphis, TN; and Wendy Landier, Lindsey Hageman, Yanjun Chen, F. Lennie Wong, and Smita Bhatia, City of Hope, Duarte, CA.
Abstract
PURPOSE: Mercaptopurine (MP) is the mainstay of curative therapy for acute lymphoblastic leukemia (ALL). We performed a genome-wide association study (GWAS) to identify comprehensively the genetic basis of MP intolerance in children with ALL. PATIENTS AND METHODS: The discovery GWAS and replication cohorts included 657 and 371 children from two prospective clinical trials. MP dose intensity was a marker for drug tolerance and toxicities and was defined as prescribed dose divided by the planned protocol dose during maintenance therapy; its association with genotype was evaluated using a linear mixed-effects model. RESULTS: MP dose intensity varied by race and ethnicity and was negatively correlated with East Asian genetic ancestry (P < .001). The GWAS revealed two genome-wide significant loci associated with dose intensity: rs1142345 in TPMT (Tyr240Cys, present in *3A and *3C variants; P = 8.6 × 10(-9)) and rs116855232 in NUDT15 (P = 8.8 × 10(-9)), with independent replication. Patients with TT genotype at rs116855232 were exquisitely sensitive to MP, with an average dose intensity of 8.3%, compared with those with TC and CC genotypes, who tolerated 63% and 83.5% of the planned dose, respectively. The NUDT15 variant was most common in East Asians and Hispanics, rare in Europeans, and not observed in Africans, contributing to ancestry-related differences in MP tolerance. Of children homozygous for either TPMT or NUDT15 variants or heterozygous for both, 100% required ≥ 50% MP dose reduction, compared with only 7.7% of others. CONCLUSION: We describe a germline variant in NUDT15 strongly associated with MP intolerance in childhood ALL, which may have implications for treatment individualization in this disease.
PURPOSE:Mercaptopurine (MP) is the mainstay of curative therapy for acute lymphoblastic leukemia (ALL). We performed a genome-wide association study (GWAS) to identify comprehensively the genetic basis of MP intolerance in children with ALL. PATIENTS AND METHODS: The discovery GWAS and replication cohorts included 657 and 371 children from two prospective clinical trials. MP dose intensity was a marker for drug tolerance and toxicities and was defined as prescribed dose divided by the planned protocol dose during maintenance therapy; its association with genotype was evaluated using a linear mixed-effects model. RESULTS:MP dose intensity varied by race and ethnicity and was negatively correlated with East Asian genetic ancestry (P < .001). The GWAS revealed two genome-wide significant loci associated with dose intensity: rs1142345 in TPMT (Tyr240Cys, present in *3A and *3C variants; P = 8.6 × 10(-9)) and rs116855232 in NUDT15 (P = 8.8 × 10(-9)), with independent replication. Patients with TT genotype at rs116855232 were exquisitely sensitive to MP, with an average dose intensity of 8.3%, compared with those with TC and CC genotypes, who tolerated 63% and 83.5% of the planned dose, respectively. The NUDT15 variant was most common in East Asians and Hispanics, rare in Europeans, and not observed in Africans, contributing to ancestry-related differences in MP tolerance. Of children homozygous for either TPMT or NUDT15 variants or heterozygous for both, 100% required ≥ 50% MP dose reduction, compared with only 7.7% of others. CONCLUSION: We describe a germline variant in NUDT15 strongly associated with MP intolerance in childhood ALL, which may have implications for treatment individualization in this disease.
Authors: J H BURCHENAL; M L MURPHY; R R ELLISON; M P SYKES; T C TAN; L A LEONE; D A KARNOFSKY; L F CRAVER; H W DARGEON; C P RHOADS Journal: Blood Date: 1953-11 Impact factor: 22.113
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Xianyun Mao; Abigail W Bigham; Rui Mei; Gerardo Gutierrez; Ken M Weiss; Tom D Brutsaert; Fabiola Leon-Velarde; Lorna G Moore; Enrique Vargas; Paul M McKeigue; Mark D Shriver; Esteban J Parra Journal: Am J Hum Genet Date: 2007-04-20 Impact factor: 11.025
Authors: Partha Krishnamurthy; Matthias Schwab; Kazumasa Takenaka; Deepa Nachagari; Jessica Morgan; Mark Leslie; Weinan Du; Kelli Boyd; Meyling Cheok; Hiromitsu Nakauchi; Catia Marzolini; Richard B Kim; Balasubramanian Poonkuzhali; Erin Schuetz; William Evans; Mary Relling; John D Schuetz Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Sijia Wang; Cecil M Lewis; Mattias Jakobsson; Sohini Ramachandran; Nicolas Ray; Gabriel Bedoya; Winston Rojas; Maria V Parra; Julio A Molina; Carla Gallo; Guido Mazzotti; Giovanni Poletti; Kim Hill; Ana M Hurtado; Damian Labuda; William Klitz; Ramiro Barrantes; Maria Cátira Bortolini; Francisco M Salzano; Maria Luiza Petzl-Erler; Luiza T Tsuneto; Elena Llop; Francisco Rothhammer; Laurent Excoffier; Marcus W Feldman; Noah A Rosenberg; Andrés Ruiz-Linares Journal: PLoS Genet Date: 2007-11 Impact factor: 5.917
Authors: Ching-Hon Pui; Dario Campana; Deqing Pei; W Paul Bowman; John T Sandlund; Sue C Kaste; Raul C Ribeiro; Jeffrey E Rubnitz; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; Larry E Kun; Sima Jeha; Cheng Cheng; Scott C Howard; Vickey Simmons; Amy Bayles; Monika L Metzger; James M Boyett; Wing Leung; Rupert Handgretinger; James R Downing; William E Evans; Mary V Relling Journal: N Engl J Med Date: 2009-06-25 Impact factor: 91.245
Authors: Hee Young Ju; Ji Won Lee; Hee Won Cho; Ju Kyung Hyun; Youngeun Ma; Eun Sang Yi; Keon Hee Yoo; Ki Woong Sung; Rihwa Choi; Hong Hoe Koo; Soo-Youn Lee Journal: PLoS One Date: 2021-01-22 Impact factor: 3.240
Authors: Caroline F Thorn; Michelle Whirl-Carrillo; Houda Hachad; Julie A Johnson; Ellen M McDonagh; Mark J Ratain; Mary V Relling; Stuart A Scott; Russ B Altman; Teri E Klein Journal: Clin Pharmacol Ther Date: 2019-01 Impact factor: 6.875
Authors: C Liu; W Yang; D Pei; C Cheng; C Smith; W Landier; L Hageman; Y Chen; J J Yang; K R Crews; N Kornegay; S E Karol; F L Wong; S Jeha; J T Sandlund; R C Ribeiro; J E Rubnitz; M L Metzger; C-H Pui; W E Evans; S Bhatia; M V Relling Journal: Clin Pharmacol Ther Date: 2016-11-18 Impact factor: 6.875
Authors: Chase C Suiter; Takaya Moriyama; Kenneth A Matreyek; Wentao Yang; Emma Rose Scaletti; Rina Nishii; Wenjian Yang; Keito Hoshitsuki; Minu Singh; Amita Trehan; Chris Parish; Colton Smith; Lie Li; Deepa Bhojwani; Liz Y P Yuen; Chi-Kong Li; Chak-Ho Li; Yung-Li Yang; Gareth J Walker; James R Goodhand; Nicholas A Kennedy; Federico Antillon Klussmann; Smita Bhatia; Mary V Relling; Motohiro Kato; Hiroki Hori; Prateek Bhatia; Tariq Ahmad; Allen E J Yeoh; Pål Stenmark; Douglas M Fowler; Jun J Yang Journal: Proc Natl Acad Sci U S A Date: 2020-02-24 Impact factor: 11.205